Compare Manulife Financial Corporation (MFC) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs Zoetis Inc — how do they compare? Manulife Financial Corporation trades at $43.98 (market cap $72.68B), while Zoetis Inc trades at $72.81 (market cap $31.14B). The key difference: Manulife Financial Corporation is far larger — about 2.3× Zoetis Inc's market cap, and Manulife Financial Corporation pays the higher dividend (3.1%). Which is the better fit depends on your goals.
| MFC | ZTS | |
|---|---|---|
Market Cap | $72.68B | $31.14B |
Sector | Financials | Health |
52-Week High | $44.77 | $156.76 |
52-Week Low | $30.06 | $71.91 |
Enterprise Value | $67.84B | $38.70B |
Dividend Yield | 3.1% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manulife Financial (MFC) trades at $44.09, down slightly by 0.14% today, with a neutral technical signal and mixed earnings performance. The company reported strong Q2 2026 results with 12% core earnings growth and 21% APE sales growth in Asia, though Q1 results missed expectations. Revenue has grown from $15.3B in 2022 to $53.0B in 2025, with net income margin at 11.7% and ROE of 13.88%. Recent partnerships with Microsoft and Alibaba Cloud highlight strategic AI investments.
MFC presents a balanced outlook with solid fundamentals and growth in Asian markets, supported by a 57% analyst buy rating and $51.50 price target. However, premium valuation (P/E 16.57, P/B 2.18) and mixed technical indicators suggest cautious optimism. Key risks include execution in wealth management, regulatory scrutiny in Hong Kong, and macroeconomic sensitivity. The stock offers steady dividends with recent $0.49 payouts.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
